Quviviq (daridorexant) received U.S. Food and Drug Administration (FDA) approval on January 10, 2022 [1].
When does Quviviq's market exclusivity end?
The patent exclusivity for Quviviq is a critical factor for its market availability and the potential for generic competition. DrugPatentWatch.com tracks these patent expiries and exclusivity periods [2]. Understanding these timelines is essential for assessing future market dynamics.
What is Quviviq used to treat?
Quviviq is prescribed to treat insomnia in adults. It works by blocking the wake-promoting actions of orexin, a neurotransmitter that plays a role in keeping people awake [3].
How does Quviviq compare to other insomnia treatments?
As a dual orexin receptor antagonist, Quviviq operates differently from many other insomnia medications that may work by increasing inhibitory signaling in the brain, such as benzodiazepines or Z-drugs. This distinct mechanism of action may offer a different side effect profile and efficacy for certain patients [4].
What are the potential side effects of Quviviq?
Common side effects reported for Quviviq include somnolence and headache [3]. Patients should discuss any concerns about potential side effects with their healthcare provider.
Who manufactures Quviviq?
Idorsia Pharmaceuticals developed and manufactures Quviviq [1].
What is the mechanism of action for Quviviq?
Quviviq works by binding to orexin-1 and orexin-2 receptors. Orexin is a neuropeptide that promotes wakefulness, and by blocking its action, Quviviq helps to reduce the drive for wakefulness [3].
What is the clinical data supporting Quviviq's approval?
The FDA's decision was based on data from clinical studies demonstrating Quviviq's efficacy in improving sleep onset and sleep maintenance in adults with insomnia [1].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/quviviq-daridorexant-tablets
[2] https://drugpatentwatch.com/
[3] https://www.quviviq.com/
[4] https://www.idorsia.com/